Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Revenue (2024 - 2025)

Monte Rosa Therapeutics' Revenue history spans 2 years, with the latest figure at $2.8 million for Q4 2025.

  • For Q4 2025, Revenue fell 95.41% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $123.7 million, up 63.54%, while the annual FY2025 figure was $123.7 million, 63.54% up from the prior year.
  • Revenue reached $2.8 million in Q4 2025 per GLUE's latest filing, down from $12.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $84.9 million in Q1 2025 to a low of $1.1 million in Q1 2024.